European approval of Trixeo Aerosphere (formoterol / glycopyrronium bromide/ budesonide) for maintenance treatment of COPD

Approval based on data from ETHOS Phase III trial, in which Trixeo showed a significant reduction in rate of moderate/severe exacerbations vs dual therapies Bevespi Aerosphere (glycopyrronium/formoterol fumarate) and PT009 (budesonide/formoterol fumarate) over 52 weeks.

PharmaTimes